The compound is studied in Phase III clinical trial in combination with azacytidine in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (reviewed in [4,59]). This evidence concerns the gene TP53 and acute myeloid leukemia.